What is the equity of Biogen this year?
Biogen has equity of 14.8 B USD this year.
In 2024, Biogen's equity was 14.8 B USD, a 10.46% increase from the 13.4 B USD equity in the previous year.
In the annual report of the Biogen share (US09062X1037, 789617, BIIB), it breaks down its revenues into 3 segments: 1. Product, 2. Other, 3. Therapeutics. The Biogen stock (WKN: 789617, ISIN: US09062X1037, Ticker Symbol: BIIB) is a leading investment for investors interested in participating in the Health Care sector.
Biogen's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Biogen's equity is essential for assessing its financial health, stability, and value to shareholders.
Evaluating Biogen's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Biogen's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Fluctuations in Biogen’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Biogen has equity of 14.8 B USD this year.
The equity of Biogen has increased/decreased by 10.46% increased compared to the previous year.
A high equity is advantageous for investors of Biogen as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
A low equity can be a risk for investors of Biogen, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
An increase in equity of Biogen can strengthen the company's financial position and improve its ability to make investments in the future.
A reduction in equity of Biogen can affect the financial situation of the company and lead to a higher dependence on debt capital.
Some factors that can affect the equity of Biogen include profits, dividend payments, capital increases, and acquisitions.
The equity of Biogen is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
To change equity, Biogen can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
Over the past 12 months, Biogen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biogen is expected to pay a dividend of 0 USD.
The current dividend yield of Biogen is .
Biogen pays a quarterly dividend. This is distributed in the months of .
Biogen paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Biogen is assigned to the 'Health' sector.
To receive the latest dividend of Biogen from 4/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/29/2024.
The last dividend was paid out on 4/29/2024.
In the year 2023, Biogen distributed 0 USD as dividends.
The dividends of Biogen are distributed in USD.
The Biogen stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank
Our stock analysis for Biogen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biogen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.